District Court Litigation and Arbitrations

We try patent cases in federal district courts across the country, before juries and judges. We also represent parties in patent-related arbitrations. Matters in which we are or were lead counsel include representing:

  • Amgen against Sandoz in the first case alleging infringement under the Biologics Price Competition and Innovation Act, against Apotex in the first trial under that Act, and against other biosimilar makers in subsequent BPCIA cases.
  • Aruba Networks against Commil, achieving a settlement on favorable terms after opening statements.
  • Biogen against Bayer Healthcare and EMD Serono in a five-week jury trial about recombinant beta-interferon.
  • Cabaret Biotech Ltd. in an action involving CAR-T cancer therapy.
  • CheckFree and Fiserv in litigation against Metavante, involving provision of electronic payment solutions to the banking industry
  • Cisco Systems against Storage Technologies, resulting in a favorable jury verdict of noninfringement and invalidity.
  • Edwards Lifesciences in litigation against Medtronic, involving transcatheter heart valve technology. Obtained a verdict of infringement and $394 million in damages. Together with related matters, this case subsequently settled with payments to Edwards totaling approximately $1.1 billion. 
  • Garmin against Silver State and against Triangle Software, prevailing before juries in each, and against Pacing Technologies, prevailing on summary judgment.
  • Genentech in litigation against, among others, Baxalta, BMS, Fresenius, GlaxoSmithKline, Human Genome Sciences, and the University of Pennsylvania, involving cancer therapeutics, hemophilia therapeutics, and recombinant antibody expression systems.
  • General Electric against Mitsubishi Heavy Industries in a trial involving wind turbine technology, obtaining a verdict of infringement and $170 million damages.
  • Google in litigation against Word To Info regarding search and machine learning technology.  The case settled favorably after claim construction.
  • Life Technologies against Enzo Biochem in a three-week jury trial involving DNA-sequencing technology.
  • Medicis Pharmaceutical Corp. in litigation against, among others, Impax Labs, Prasco, Mylan, Ranbaxy, Sandoz, Barr Laboratories, and Lupin, involving Hatch-Waxman challenges to Medicis’s SOLODYN® product.
  • Natera in litigation against Invitae Corp., involving DNA-sequencing technology.
  • Nearmap US in litigation against Eagle View Technologies, involving automated modeling of ground structures from aerial imagery.
  • Take-Two Interactive Software and Rockstar Games in cases against McRO involving computer animation technology. 
  • Twitter in litigation against Blackberry. Obtained ruling on motion to dismiss invalidating four of seven asserted patents as ineligible under Section 101.
  • Vanda Pharmaceuticals against generic-drug manufacturers in Hatch-Waxman trials about both Fanapt® (iloperidone) and Hetlioz® (tasimelteon), including a trial victory affirmed on appeal in a leading Hatch-Waxman case